Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
15-Feb-2013 Business Profile
Aventis Pharma (AVENTIS), previously known as Hoechst Marion Roussel (HMR), is a 50.1 % subsidiary of Aventis (formed by the merger of Hoechst AG and Rhone Poulenc). In 1999, the life sciences business of Hoechst AG and Rhone Poulenc SA were formally merged into a global life sciences giant called Aventis. The pharmaceutical business of both the companies has been combined into Aventis Pharma AG. The domestic product portfolio of Aventis Pharma includes 29 brands, 12 of which fall under the purview of the current DPCO. Some of its prominent brands include Cardace, Amaryl, Rabipur, Clexane, Lantus, ..etc.
Aventis focuses its activities on seven major therapeutic areas including cardiovascular diseases, thrombosis, oncology, central nervous system disorders, metabolic disorders, internal medicine and vaccines. With more than 99,000 employees in 100 countries across five continents, Sanofi-Aventis holds 5.3% of the global market share in healthcare. The company has Aventis Pharma Deutschland GmbH, Germany; PT Aventis Pharma, Indonesia; Aventis Pharmaceuticals Inc., USA; Aventis Pharma PTE, Singapore; Aventis Pharma, (U.K.) Investment et al as its subsidiaries. It holds 49% in its JV Chiron Behring Vaccines (CBVPL).
The company reported fall of 6.39% in standalone net profit on y-o-y basis to Rs 513.00 million, while total income rose 23.37% y-o-y basis to Rs 4.04 billion for the quarter ended September 2012.
The Andhra Pradesh High Court (HC) on Friday ruled that Sanofi need not pay tax in India. Meanwhile, tax has to be paid for acquisiton of Shantha biotech.
Aventis Pharma has posted a net profit of Rs 361 million for the quarter ended December 31, 2011 as compared to Rs 1,049 million for the quarter ended December 31, 2010, representing decrease of 65.59%.
Aventis Pharma has announced that it has closed the definitive agreement with Universal Medicare on fulfillment of all the conditions precedent.
Aventis Pharma has entered into an agreement to acquire Universal Medicare`s business of marketing and distribution of nutraceutical formulations in India.
The company announced that it has agreed to exit its joint venture, Chiron Behring Vaccines (P) by selling its 49% shareholding to its nominee partner Novartis Pharma AG.
Angel Broking has recommended `Sell` on Aventis Pharma with a price target of Rs 1,658 as against the market price (CMP) of Rs 1,979 in its report dated July 19, 2010.
Aventis Pharma`s net profit for the quarter ended Jun.30, 2010 stood at Rs 424 million fall of almost 10% against Rs 471 million in the same quarter previous year.
Drug maker, Aventis Pharma is slated to announce its Q2CY2010 results. Angel Broking expects the company to report a rise of 10.30% in net sales to Rs 2,757 million as against Rs 2,499 million with operating profit margin (OPM) estimated to contract to 18.30% as against 21.20%. As a result, net profit is expected to remain flat at Rs 482 million as against Rs 471 million on the back of lower OPM. The stock is currently trading at 24.8x CY2010E and 21.7x CY2011E earnings